Josh Eckman


Since founding Carterra (formerly Wasatch Microfluidics) in 2005, Mr. Eckman has been instrumental in securing funding, attracting key employees and advisors, developing strategic partnerships, designing Carterra’s proprietary flexible manufacturing process, securing international distributorships, and building out the sales channels for current products. Mr. Eckman previously worked with the Lassonde New Venture Development Center, moving university technologies into the marketplace. Mr. Eckman graduated summa cum laude in Business Administration and Asian Studies from the University of Utah. At graduation, he was awarded the Outstanding Scholar in Business Administration and the Honors Baccalaureate Award. Mr. Eckman also received a M.S. in Mechanical Engineering (microfluidics focus) from the University of Utah.

Yasmina Noubia Abdiche, PhD

Chief Scientific Officer (CSO)

Dr. Abdiche joined Carterra as CSO in 2016 after twelve and half years’ experience in the pharmaceutical industry at Rinat-Pfizer, where she was a Research Fellow, a member of Rinat’s leadership team, served on the governing committee for Pfizer’s Postdoctoral Program, and led a group of analytical scientists that applied label-free biosensors to the discovery of therapeutic antibodies. After graduating from Oxford University in the UK with a PhD in Biological Chemistry and a Master’s degree in Chemistry, Dr. Abdiche completed postdoctoral research in Dr. David Myszka’s laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions. Dr. Abdiche is co-inventor of several therapeutic antibodies in clinical trials, including Teva’s fremanezumab (formerly TEV-48125, RN-307) an anti-CGRP antibody which successfully completed PhIII clinical trials for chronic migraine and is expected to achieve US market approval in 2018, bococizumab, a PCSK9 inhibitor that was tested in PhIII clinical trials for hypercholesteremia, and RN888, a PD-1 inhibitor currently in PhI clinical trials for cancer immunotherapy.

Tim Germann

Vice President, Global Sales and Service

Tim Germann leads our customer-facing functions—sales, service, and support.  He is a sales and operational leader who has built or rebuilt commercial teams and revenue streams in the life sciences and healthcare for more than 25 years.  His successful tenures include Molecular Devices (now Danaher), Affymetrix (now Thermo Fisher), Metabolon, and Hill-Rom.  At Hill-Rom, Tim led the global commercial operation for the healthcare IT division which drove more than $300 million of increased valuation in the business during a five-year turnaround.  Most recently, Mr. Germann was COO and Chief Commercial Officer at RF Technologies where he led successful revitalization and growth initiatives across sales, marketing, service, finance, and manufacturing.  Tim graduated from the Marriott School of Management at Brigham Young University and established a successful management consulting practice prior to joining Carterra.

Julian A. Abery, MSc

Vice President, Marketing

With over 20 years of bio-industry experience, gained in both scientific and commercial roles, Julian brings a wealth of expertise in sales development and expansion for instrumentation and contract research services. Julian has strong international experience, having held senior scientific, commercial and management positions at leading biotech, instrumentation and service providers, including: Xenova Discovery Ltd (UK); Biacore AB (Sweden, now part of GE Healthcare); Amphora Discovery Corp. (USA); and multiple technology start-ups (USA & Europe) through his consultancy company. Julian earned a BSc in Clinical Biochemistry and his Master’s degree in Analytical Chemistry from the University of Greenwich, London, UK.